Worldwide, lung cancer stands as a leading cause of mortality, with EGFR-mutated metastatic non-small cell lung cancer (NSCLC) accounting for a large percentage of cases in the Indian population. Different generations of EGFR-tyrosine kinase inhibitors (TKIs) are available to treat EGFR-mutated NSCLC. The purpose of our research was to evaluate and compare the superiority of osimertinib over gefitinib/erlotinib in terms of clinical effectiveness and safety.
Methods
A retrospective observational cohort study was conducted at the Clinical Oncology Center in the Western region of India. Patients suffering from EGFR-mutated metastatic NSCLC were recruited for the study. The response of EGFR-TKIs was assessed using objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and incidence of adverse events (AE).
Results
A total of 75 patients treated with EGFR TKIs were enrolled in the study. The ORR of osimertinib and gefitinib/erlotinib was 11.11% and 25.64% (p = 0.142) and DCR was found to be 69.44% and 82.05% (p = 0.28) respectively. Osimertinib and gefitinib/erlotinib had respective median PFS of 8.43 and 10.68 months. The incidence of AE of osimertinib and gefitinib/erlotinib was 1.94 and 2.49 respectively.
Conclusion
Osimertinib was not found to be superior over gefitinib/erlotinib based on clinical effectiveness. Though it showed a better safety profile, the cost of the treatment of osimertinib over gefitinib/erlotinib was not justifiable.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71: 209–249.
2.
SathishkumarKChaturvediMDasP, et al.Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. Indian J Med Res2022; 156: 598–607.
3.
FerlayJColombetMSoerjomataramI, et al.Cancer statistics for the year 2020: an overview. Int J Cancer2021; 149: 778–789.
4.
FerlayJEMLFLaversanneMColombetM, et al.Global cancer observatory: cancer today (version 1.1). Lyon, France: International Agency for Research on Cancer, 2024, https://gco.iarc.who.int/today.
5.
ZappaCMousaSA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res2016; 5: 288–300.
6.
ZhaoHRenDLiuH,et al.Comparison and discussion of the treatment guidelines for small cell lung cancer. Thorac Cancer2018; 9: 769–774.
7.
CarboneDPMorgenszternDLe MoulecS, et al.Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing,≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study. Am Soc Clin Oncol2018; 36: 8507. doi:https://doi.org/10.1200/JCO.2018.36.15_suppl.8507
8.
EttingerDSAkerleyWBeplerG, et al.Non–small cell lung cancer. J Natl Compr Cancer Network2010; 8: 740–801.
9.
ReckMHeigenerDFMokT, et al.Management of non-small-cell lung cancer: recent developments. Lancet2013; 382: 709–719.
10.
HerbstRSMorgenszternDBoshoffC. The biology and management of non-small cell lung cancer. Nature2018; 553: 446–454.
11.
KumariNSinghSHaloiD, et al.Epidermal growth factor receptor mutation frequency in squamous cell carcinoma and its diagnostic performance in cytological samples: a molecular and immunohistochemical study. World J Oncol2019; 10: 142–150.
MetroGCrinòL. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res2012; 1: 5.
14.
HaSYChoiS-JChoJH, et al.Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget2015; 6: 5465–5474.
15.
MarchettiAMartellaCFelicioniL, et al.EGFR Mutations in non–small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol2005; 23: 857–865.
16.
YangJC-HWuY-LSchulerM, et al.Afatinib Versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol2015; 16: 141–151.
17.
ZhouCWuY-LChenG, et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol2011; 12: 735–742.
18.
SequistLVYangJC-HYamamotoN, et al.Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol2023; 41: 2869–2834.
19.
RosellRCarcerenyEGervaisR, et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol2012; 13: 239–246.
20.
MokTSWuY-LThongprasertS, et al.Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med2009; 361: 947–957.
21.
TakedaMNakagawaK. First-and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer?Int J Mol Sci2019; 20: 46.
22.
PaselloGLorenziMScattolinD, et al.Osimertinib in patients with treatment-naive EGFR-mutant non-small cell lung cancer: overall survival, post-progression management and budget impact analysis in real-world. Oncologist2024; 29: 596–608. doi:https://doi.org/10.1093/oncolo/oyae043
23.
MokTSWuY-LAhnM-J, et al.Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med2017; 376: 629–640.
24.
SoriaJ-COheYVansteenkisteJ, et al.Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med2018; 378: 113–125.
25.
HsuW-HYangJ-HMokT,et al.Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol2018; 29: i3–i9.
26.
RussoAFranchinaTRicciardiGRR, et al.A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives. Oncotarget2015; 6: 26814.
27.
WestoverDZugazagoitiaJChoB, et al.Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol2018; 29: i10–ii9.
28.
KosakaTYamakiEMogiA,et al.Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. BioMed Res Int2011; 2011: 1–7. doi:https://doi.org/10.1155/2011/165214
29.
ShahRLesterJF. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations. Clin Lung Cancer2020; 21: e216–e228.
30.
TanC-SKumarakulasingheNBHuangY-Q, et al.Third generation EGFR TKIs: current data and future directions. Mol Cancer2018; 17: 1–14.
31.
RamalingamSReungwetwattanaTChewaskulyongB, et al.Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Ann Oncol2017; 28: v635.
32.
RamalingamSGrayJOheY, et al.Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis. Ann Oncol2019; 30: v914–v9v5.
33.
HochmairMMorabitoAHaoD, et al.Afatinib Followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: a real-world study (GioTag). Ann Oncol2018; 29: ix176–ixix7.
34.
LorenziMFerroACecereF, et al.First-line osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: outcome and safety in the real world: FLOWER study. Oncologist2022; 27: 87–e115.
35.
LauSCChoobackNHoC,et al.Outcome differences between first-and second-generation EGFR inhibitors in advanced EGFR mutated NSCLC in a large population-based cohort. Clin Lung Cancer2019; 20: e576–e83.
36.
DuchateauCSStokkelMP. Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival. CHEST Journal2005; 127: 1152–1158.
37.
QuoixE. Advanced non-small cell lung cancer in elderly patients. Breathe2012; 9: 26–34.
38.
VoraNReckampKL. Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol2008; 35: 590–596.
SaitoSEspinoza-MercadoFLiuH, et al.Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther2017; 18: 359–368.
41.
YanoTHaroAShikadaY, et al.Non-small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: epidemiology and clinical features. Int J Clin Oncol2011; 16: 287–293.
42.
NakamuraHAndoKShinmyoT, et al.Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg2011; 17: 469–480.
43.
KotaRGundetiSGullipalliM, et al.Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients. Lung India2015; 32: 561–565.
44.
GrahamRPTreeceALLindemanNI, et al.Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Laborat Med2018; 142: 163–167.
45.
LiXZhaiZZhuY,et al.Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation. Pak J Med Sci2022; 38: 1589.
46.
OheYImamuraFNogamiN, et al.Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol2019; 49: 29–36.
47.
TatineniVO’SheaPJOzairA, et al.First-versus third-generation EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with brain metastases. Cancers (Basel)2023; 15: 2382.
48.
ChoBCChewaskulyongBLeeKH, et al.Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. J Thorac Oncol2019; 14: 99–106.
